Modality
Gene Therapy
MOA
MALT1i
Target
KRASG12C
Pathway
Tau
Prostate Ca
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Jul 2029
Phase 1Current
NCT07013255
2,597 pts·Prostate Ca
2023-07→2029-07·Recruiting
NCT04900777
1,052 pts·Prostate Ca
2018-05→2029-02·Not yet recruiting
3,649 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-132.9y awayPh2 Data· Prostate Ca
2029-07-243.3y awayPh2 Data· Prostate Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2029-02-13 · 2.9y away
Prostate Ca
Ph2 Data
2029-07-24 · 3.3y away
Prostate Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07013255 | Phase 1/2 | Prostate Ca | Recruiting | 2597 | PASI75 |
| NCT04900777 | Phase 1/2 | Prostate Ca | Not yet recr... | 1052 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |